RRP Researcher's paper claims no additional trial study is necessary to approve 3107, results of currently available studies are sufficient to prove 3107s superiority over PGEN's gorilla adenovirus

Boeing agreed on a proposal for the membership with their union, awaiting formal member vote. This sets up Boeing's manufacturing for the next phase of increased production, under CEO Ortberg. Seems like a competent manufacturing engineer at the helm. Instead of financial stock pumping which put BA in the worst possible situation in 2018.

"...Technology

See also: COVID-19 vaccine clinical research § Trial and authorization status

The Inovio technology is based on inserting engineered DNA into cells, where it becomes transcribed into mRNA and translated into proteins. The proteins encoded by the DNA elicit immune response to antigens from cancers and viruses, by stimulating the production of T cells and antibodies that aid recovery.^([6]) The technology can be "targeted" to specific types of cancer and immune diseases, such as those produced by a virus.^([6])

During a meeting of the White House Coronavirus Task Force in March 2020, CEO, Joseph Kim, said that Inovio scientists had designed a vaccine candidate (INO-4800) for the COVID-19 coronavirus in January, in three hours, after the virus' genetic sequence was first published.^([7])

Shareholders sued Inovio in August 2020, claiming it exaggerated evidence of its coronavirus vaccine's efficacy in order to boost its stock price.^([8])

License of electroporation device

In 2006, Inovio licensed "certain patented technology relating to the delivery of gene-based therapeutics into skin", as well as patents "involving the delivery of genes or drugs via ex vivo, intratumoral and intramuscular electroporation... The ex-vivo patents are relevant to the delivery of genes to dendritic and stem cells."^([9])

Licence of US7328064B2

Sometime after its publication in February 2008, Inovio was assigned a patent for "an apparatus [that provides] for injecting a fluid into body tissue, the apparatus comprising: a hollow needle; and a fluid delivery means, wherein the apparatus is adapted to actuate the fluid delivery means in use so as to automatically inject fluid into body tissue during insertion of the needle into the said body tissue."^([10])

Cellectra injection device

To facilitate use of its potential products, Inovio manufactures a proprietary injection device, called "Cellectra", which the company describes as providing a "brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA."^([11]) The small device, which runs on "AA" batteries, is designed for use in the field under the difficult conditions of an epidemic.^([12])

In June 2020 – in anticipation of the Inovio COVID-19 vaccine candidate becoming successful – the US Department of Defense invested US$71 million to further develop Cellectra as a handheld device and to preorder an undisclosed number of the devices.^([13])

Vaccine development

See also: COVID-19 vaccine

Inovio's logo prior to 2020

In a 2016 dose-escalation Phase I clinical trial to assess safety after intramuscular injection in healthy adults, the Inovio vaccine candidate, INO-4700 (also called GLS-5300) for development against Middle East respiratory syndrome (MERS) coronavirus, proved to be safe with only mild symptoms and no adverse effects.^([14]) The trial also demonstrated immunogenicity by dose-independent immune responses detected in more than 85% of subjects after two vaccinations that were durable a year later.^([14])

In 2016, Inovio was involved, along with their partners GeneOne Life Science, in an attempt to control the Zika virus outbreak in Miami. In fact, they "were the first to initiate a human Zika DNA vaccine trial... [for] the safety, tolerability, and immunogenicity of GLS-5700 in 40 healthy adults. The trial's estimated completion date is November 2017." Then in Puerto Rico, where a Zika emergency had been declared, they did a study with 160 previously healthy adults using their proprietary "Cellectra-3P" technology.^([15]) Preliminary results for the Miami trial were self-reported at the end of 2017.^([16])^([17])

In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.^([7])^([18]) Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.^([5]) In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.^([19]) In May 2021, Inovio announced the results of preclinical studies on a "pan-SARS-CoV-2" DNA vaccine (INO-4802) and plans to initiate phase I/II studies. The vaccine incorporates common overlapping mutations from several SARS-COV-2 variants of concern isolated from several different countries including Brazil and India.^([20])

Partnerships

In January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would grant of up to $9 million to Inovio for development of a vaccine against SARS-CoV-2.^([21]) Inovio has partnerships to develop its COVID-19 vaccine candidate with CEPI, the South Korean National Institute of Health, and the International Vaccine Institute.^([2)^(...")

U.S. & Europe	Very low risk	Travel screening, rapid isolation, strong systems U.S. & Europe Very low risk Travel screening, rapid isolation, strong systems

"What current modeling says

• Outbreak center (Ituri, DRC + Uganda): CDC projections show that if only ~20% of patients are effectively isolated, there’s a high chance the outbreak could grow into tens of thousands of cases within a few months.
• If ~70% of patients are isolated and treated, the probability of a very large outbreak (≥10,000 cases in 3 months) drops to about 5%.
• A Lancet modeling study on the same 2026 Bundibugyo outbreak highlights substantial spillover risk within the region, but emphasizes that strong, rapid interventions sharply cut transmission.

Risk to the U.S. over the next months

• CDC’s formal assessment: overall risk to the U.S. population over the next 3 months is low, mainly because:
  • Very few travelers from the outbreak zone
  • Robust airport screening and isolation protocols
  • Prior experience with Ebola response (2014–2016)

Extend that logic to 6 months: unless travel patterns or outbreak size change dramatically, the likelihood of Ebola transmission in the U.S. remains very low, even though the impact of any imported case would be serious.

The honest bottom line

• Locally (DRC/Uganda): Ebola’s “infection capability” over 6 months is highly dependent on how fast and thoroughly cases are found and isolated.
• Globally, especially U.S./Europe: risk is low but not zero—it’s more about preparedness than prediction.

DRC & Uganda (outbreak zone)	High, but controllable	Local containment, isolation, contact tracingDRC & Uganda (outbreak zone) High, but controllable Local containment, isolation, contact tracing

Neighboring African countries	Low–moderate spillover risk	Cross‑border movement, health system strengthNeighboring African countries Low–moderate spillover risk Cross‑border movement, health system strength

MS COPILOT:

"

Feature	VGX‑3100 (ApolloBio/INOVIO)	Current China HPV treatment pipeline (mainstream)
Type	Therapeutic DNA immunotherapy	Prophylactic vaccines + surgical treatments
Target	HPV‑16/18 high‑grade precancer (CIN2/3 HSIL)	Prevention of HPV infection; excision of lesions
Stage in China	Phase 3 successful; pre‑NDA	Approved vaccines; standard surgical care
Route	Intramuscular + electroporation (CELLECTRA)	IM vaccines; surgical procedures (LEEP, conization)
Goal	Clear HPV + regress lesions, avoid surgery	Prevent infection or remove diseased tissue

Institutions and Hedge funds own = 26.79% of shares- they are playing for our side from the Big Boys' team. Note our 50 day moving average was $1.03 as of yesterday. Evidently rising as shares have traded ~$1.15 plus or minus this week.

The attempt to push inovio below $1 failed and the team of shorts are looking at huge losses on the 16 million short shares they borrowed and have to return. Inovio will never be delisted from the Nasdaq stock exchange. The squeeze will continue through next week for the monthly stock expiration date will require shorts to cover or else continue to pay for their underwater positions. Profitez mes amis, the money will flow in through Friday close of the market. Note we’re on the verge of the issue price of the company’s $18 million share sale at $1.10, which is not yet available for sale yet, but check the date shares become available for your own information. This may present a temporary ceiling price for shares; but the $18 million dollars will extend the company runway for launching Ino-3107, following the 10/30/26 expected PDUFA date- after which will bring product sales revenues. Btw consider the influence that ApolloBio sales of 3100 will have on the share price- 11% is inovio’s % of the profit and analysts value the company around $4. Don’t tell the short schmucks about that, please- we need them to keep selling us cheap shares (!)

Grok finds 3 forecasts for Inovio price in 2027 from $2.50-$4 and is my first time using Grok.

From (revised previous) post about the value of the Ino-Apollobio 3100 profitsharing agreement with ApolloBio from Stocktwits.com:

"...If I recall, the profit sharing % is in the low teens, probably a sliding rate based on volume, between 11%-14%; I believe ApolloBio is aiming for a worldwide license; so the market per WHO estimate is 167 million cases...will take time to deliver all that product but a long term agreement worth, assume $900 per treatment, 50% profit per shot, $450 *165 million treatments= $75 million; as to which (?) 11% is =$8.2 million cumulatively, per the agreement. In effect a deferred revenue source of $8.2MM per share. Wall Street values the shares at 8.76 times Book Value, hence $72 MM in future Sales assumed, $72MM cash revenue less expenses $24 MM/yr. = net earnings $48 MM so Book Value $48MM; X 8.76,= $420MM div. by 100# MM shares= $4.20 a share.

All for under a buck a better deal than a pack of beer nuts.

Vaccine assault led by HHS Seceratry

The related dilution is likely to create many times more sales from the pipeline cancer and infectious disease treatments awaiting approval with self funded regulatory approvals.

INO has greater potential to work with non-US BP manufacturers or is it my imagination?? ApolloBio and AZN being 2 examples.